2025 United States Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 United States Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antisense and RNAi therapeutics market are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, and Arbutus Biopharma. Ionis Pharmaceuticals leads with extensive FDA-approved antisense drugs targeting neurological and rare diseases, advancing oligonucleotide chemistry and drug delivery innovations. Alnylam Pharmaceuticals is notable for its siRNA therapeutics, with approved products like Onpattro and Givlaari, focusing on hereditary and rare diseases. Sarepta Therapeutics specializes in RNA-based therapies for rare genetic disorders, while Arbutus Biopharma is involved in RNAi therapeutic development with emphasis on advanced delivery platforms.
These companies benefit from favorable U.S. regulatory frameworks, substantial government and private funding, and strategic collaborations with biotech and pharmaceutical firms. They actively develop improved delivery technologies such as lipid nanoparticles and GalNAc conjugates. The growing clinical approvals for RNA-based drugs and focus on rare and neurological diseases further drive their market leadership in the U.S., which holds over 60% of the global market share.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antisense and RNAi therapeutics market are Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, and Arbutus Biopharma. Ionis Pharmaceuticals leads with extensive FDA-approved antisense drugs targeting neurological and rare diseases, advancing oligonucleotide chemistry and drug delivery innovations. Alnylam Pharmaceuticals is notable for its siRNA therapeutics, with approved products like Onpattro and Givlaari, focusing on hereditary and rare diseases. Sarepta Therapeutics specializes in RNA-based therapies for rare genetic disorders, while Arbutus Biopharma is involved in RNAi therapeutic development with emphasis on advanced delivery platforms.
These companies benefit from favorable U.S. regulatory frameworks, substantial government and private funding, and strategic collaborations with biotech and pharmaceutical firms. They actively develop improved delivery technologies such as lipid nanoparticles and GalNAc conjugates. The growing clinical approvals for RNA-based drugs and focus on rare and neurological diseases further drive their market leadership in the U.S., which holds over 60% of the global market share.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
